Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL — Stella

Home/Non Hodgkin Lymphoma/IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

View on ClinicalTrials.gov

Recruiting

Back to Non Hodgkin Lymphoma trials

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of Texas Southwestern Medical Center, Dallas, Texas

Key details

Phase

Early testing / Safety & dosing

Sponsor

University of Texas Southwestern Medical Center

Collaborators

Actinium Pharmaceuticals

Enrollment target

~30 participants

Started

April 2025

Primary completion

May 2029

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.